Recruiting

MZRW

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07091084

Conditions

Constipation

Cancer

Functional Constipation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MZRW

Study Details

Brief summary:

The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the effect MZRW has on the gut microbiome. The gut microbiome is a diverse community of microorganisms living in the digestive system, essential for digestion and immune function.

Conditions

Constipation

Cancer

Functional Constipation

Study ID

NCT07091084

Start date

Jul 15, 2025

Status verified date

May, 2026

Completion date

Jul 15, 2028

Anticipated

Primary completion date

Jul 15, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 18 years or greater;
  • A diagnosis of cancer with no restrictions placed on type of cancer or stage;
  • Completed surgery, chemotherapy, immunotherapy, and/or radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;
  • Karnofsky functional score of ≥ 60;
  • Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:

  • Straining more than 25% of defecations.
  • Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.
  • Sensation of incomplete evacuation more than one-fourth (25%) of defecations.
  • Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations.
  • Manual maneuvers to facilitate more than one-fourth (25%) of defecations.
  • Fewer than three spontaneous bowel movements per week.
  • Loose stools are rarely present without the use of laxatives.
  • Insufficient criteria for irritable bowel syndrome.
  • Patient should be able to understand and complete all study assessments on their own
  • Patient should be able to understand and provide signed informed consent in English.

Table 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria\*

1. Must include two or more of the following:\*\*
2. Straining during more than ¼ (25%) of defecations
3. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations
4. Sensation of incomplete evacuation more than ¼ (25%) of defecations
5. Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations
6. Fewer than three SBM per week
7. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)

9\. Loose stools are rarely present without the use of laxatives 9. Insufficient criteria for irritable bowel syndrome Note \*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Exclusion Criteria:

  • Patients who have allergic history to herbs or Chinese medicine;
  • Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL/min/1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);
  • Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;
  • Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;
  • Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.

Study Design

Enrollment

70 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MZRW

Participants will receive 2 weeks of MZRW

no intervention: Placebo

Participants will receive 2 weeks of placebo

Interventions

MZRW

MZRW herbal formula consists of a 7:1 extract of Huo Ma Ren \[Hemp Seed 33.4%\]; Da Huang (Sheng) \[Rhubarb (Fresh) 22.2%\]; Bai Shao \[Peony (White) 11.1%\]; Zhi Shi \[Aurantium Immaturus 11.1%\]; Hou Po \[Magnolia Bark 11.1%\]; and Xing Ren \[Apricot Kernel 11.1%\] - Taken for 2 weeks intervention and 2 weeks follow-up

Primary outcome measure

  • Difference of spontaneous bowel movements (SBMs) from baseline to week 2 [ Time Frame: 2 weeks ]

Central Contacts and Locations

Central contacts

Yen Nien (Jason) Hou, PharmD

646-608-8555houy@mskcc.org

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Jun Mao, MD, MSCE

646-608-8552

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Jun Mao, MD, MSCE

646-608-8552

Memorial Sloan Kettering Bergen (All Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Jun Mao, MD, MSCE

646-608-8552

Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Jun Mao, MD, MSCE

646-608-8553

Memorial Sloan Kettering Westchester (All Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Jun Mao, MD, MSCE

646-608-8552

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Jun Mao, MD, MSCE

646-608-8552

Memorial Sloan Kettering Nassau (All Protocol Activities)

Recruiting

Rockville Centre, New York, United States, 11553

Contacts

Jun Mao, MD, MSCE

646-608-8552

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

May 22, 2026

Last verified

May, 2026

Keywords

  • constipation
  • functional constipation
  • Ma-Zi-Ren-Wan
  • MZRW
  • 25-076
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-05-22.